About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Glenmark Pharmaceuticals Ltd.
Change Company
BSE Code
532296
ISIN Demat
INE935A01035
Book Value
879.93
NSE Code
GLENMARK
Dividend Yield %
0.12
Market Cap
579499.36
P/E
38.98
EPS
52.69
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
05-Sep-2025
Glenmark Pharmaceuticals initiates multi-country ...
05-Sep-2025
Glenmark Pharmaceuticals surges on initiating mul...
02-Sep-2025
Glenmark Pharmaceuticals’ arm to launch Eribulin ...
02-Sep-2025
Glenmark Pharmaceuticals informs about media rele...
21-Aug-2025
Glenmark Pharma makes remaining investment of Rs ...
21-Aug-2025
Glenmark Pharma gains on making remaining investm...
19-Aug-2025
Glenmark Pharmaceuticals’ arm to launch Micafungi...
19-Aug-2025
Glenmark Pharmaceuticals informs about media rele...
16-Aug-2025
Glenmark Pharmaceuticals reports 86% drop in Q1 c...
14-Jul-2025
Glenmark Pharmaceuticals gets warning letter for ...
11-Jul-2025
Glenmark Pharmaceuticals’ arm enters into licensi...
11-Jul-2025
Glenmark Pharmaceuticals zooms as its arm enters ...
01-Jul-2025
Glenmark Pharmaceuticals informs about details of...
24-Jun-2025
Glenmark Pharmaceuticals launches TEVIMBRA in Ind...
24-Jun-2025
Glenmark Pharmaceuticals informs about media rele...
Page
1
of
4
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.